Opportunity for ALLR Investors
LOS ANGELES, Oct. 23, 2024 — The Schall Law Firm, a leader in shareholder rights litigation, highlights a class action lawsuit against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) ALLR for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Investors who bought Allarity securities between May 17, 2022, and July 19, 2024, are urged to reach out to the firm by November 12, 2024.
If you suffered a loss, seize the chance to participate in the lawsuit.
Contact Brian Schall of the Schall Law Firm in Los Angeles to explore your rights. Remember, until the class is certified, you are not represented by an attorney. Choose action or be an absent class member.
The Complaint alleges that Allarity made false statements to the market. The company and its executives engaged in illegal actions related to Dovitinib NDA and/or the Dovitinib-DRP PMA. This put the company under the microscope of regulatory scrutiny. Allarity downplayed the risk of enforcement post an investigation announcement. Investors were misled throughout the class period, leading to financial losses once the truth surfaced.
Join the case to recover your losses, as The Schall Law Firm is dedicated to representing investors globally and specializes in securities class action lawsuits.
This release may be deemed Attorney Advertising in certain jurisdictions.
Contact The Schall Law Firm:
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/allr-investors-have-opportunity-to-lead-allarity-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302284145.html
SOURCE: The Schall Law Firm
